Are patients happy? This simple question could shake up clinical trials

The migration to DCTs is helping uncover critical gaps in patient experience.

By Kelly Bilodeau • March 4, 2022

Exscientia scored the largest AI deal with a Big Pharma to date — but it's just getting started

The company’s CEO on the road ahead for AI capabilities in pharma.

By Meagan Parrish • March 4, 2022

Explore the Trendline➔

Oncology R&D

Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.   

By PharmaVoice staff

Woman of the Week: Lyndra Therapeutics' CEO Dr. Trish Hurter

With Lyndra's ultra-long-acting therapies, Hurter and the company are aiming to reinvent medicines.

By Taren Grom • March 2, 2022

The 2022 PharmaVoice 100 — new look, same drive for excellence

Some of the industry’s biggest names have been on our list of honorees. Now it’s time to find this year’s inspiring leaders.  

By Taren Grom • Feb. 28, 2022

Candel's CEO looks to help ignite a new era of cancer treatments

Candel Therapeutics is advancing a next-gen approach in oncology: using viruses to kill cancer cells at the site of injection.

By Taren Grom • Feb. 28, 2022

Why plasma derived therapies have a unique edge in rare diseases

Takeda's head of PDT R&D explains how the Japanese drug giant is advancing these emerging treatments.

By Kim Ribbink • Feb. 25, 2022

Guadalupe Hayes-Mota's 'recipe' for tackling pharma's supply chain issues

A quest to expand access to medical treatment globally led to a new career path when Guadalupe Hayes-Mota left his biotech leadership roles to start his own company. 

By Robin Robinson • Feb. 25, 2022

Eisai's mission to shake off Aduhelm's shadow and bring another AD drug to market

The company's senior VP of clinical research on how they're building off the science of Aduhelm to develop better Alzheimer's treatments.

By Kelly Bilodeau • Feb. 23, 2022

QSAM's rare cancer treatment could be a game-changer

For patients with osteosarcoma, amputation can be the only option — but QSAM's CEO hopes to change that.

By Alexandra Pecci • Feb. 17, 2022

Woman of the Week: Organon's Chief Commercial Officer Susanne Fiedler

Susi Fiedler, chief commercial officer, was instrumental in the spinout of Organon as a standalone company focused on a broad range of women’s health issues.

By Taren Grom • Feb. 16, 2022

How Veru is developing blockbuster drugs while avoiding biotech's 'valley of death'

Why sexual health and telemedicine are key to the company's goals in oncology.

By Meagan Parrish • Feb. 16, 2022

How a 'powerful form' of data capture is transforming pharma labs

AnIML, an open data format, is helping the industry build labs of the future.

By Robin Robinson • Feb. 15, 2022

Industry executives on the milestone moments shaping pharma's future

Scientific, technological, and communication changes that are making a permanent impact on the industry.

By Taren Grom • Feb. 9, 2022

Innovation vs. invention

IDEA Pharma’s indices ranks how well companies turn ideas into commercialized pharma products.

By Taren Grom • Feb. 9, 2022

Saniona's CEO on why it takes a village to develop treatments for a rare disease

Saniona built its village by first hiring a head of patient advocacy.

By Kim Ribbink • Feb. 8, 2022

Gaining real-world results from a decentralized trial

Lark’s principal Investigator OraLee Branch hopes a DCT will lead the company to their true audience.

By Kelly Bilodeau • Feb. 8, 2022

Why 23andMe's first solo clinical trial is a big deal

It's the first test for a compound developed with the help of the company's genetic data — and there could be plenty more to come. 

By Taren Grom • Feb. 7, 2022

Pharma's pain points with AI

Looking beyond the buzz and at the challenges associated with AI.

By Meagan Parrish • Feb. 7, 2022

Safety Monitoring: What does ePRO have to do with it?

Safety monitoring is critical to clinical trials. Learn how ePRO can play a role. Read the article.

Feb. 7, 2022

Komodo Health's partnership with Chan Zuckerberg Initiative gives 50 rare disease patient organizations access to next-generation analytics

With 330 million patient healthcare encounters in its database, Komodo assists advocacy organizations in gaining insights on specific patient populations.

By Robin Robinson • Feb. 3, 2022

PTC's vice president of patient relations outlines the importance of patient input in rare disease R&D

You can't know what matters to rare disease patients unless you ask them.

By Kim Ribbink • Feb. 3, 2022

New Capsida Biotherapeutics CEO Peter Anastasiou aims to bring AAV therapy to reality

Read what Capsida CEO Peter Anastasiou has planned for his new role. 

By Taren Grom • Feb. 3, 2022

Biopharma's R&D leaders on how technology can accelerate drug development

How emerging digital tools are providing enhanced clinical insights and improved trial results.

By Taren Grom • Jan. 27, 2022

Sanofi's chief scientist on why 'this is the moment' for AI in Big Pharma

How a $5.2 billion AI investment is enabling the French pharma to accelerate drug development. 

By Meagan Parrish • Jan. 27, 2022

With its wealth of patient data, Walgreens is looking to disrupt the clinical trial space

How the mega-pharmacy’s clinical trials officer is looking to capitalize on its deep well of patient data to create an interconnected healthcare system of the future.

By Taren Grom • Jan. 26, 2022